Status:
COMPLETED
Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
St-Augustinus Wilrijk
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
The rationale of this randomized phase II study is to investigate the feasibility of sequenced densified FEC and docetaxel based regimens in patients with primary operable high-risk breast cancer. Sev...
Detailed Description
Arm A: The three cycles of conventional FEC followed by three cycles of docetaxel regimen will be given at the following doses: Fluorouracil 500 mg/m² by i.v. bolus or infusion, Epirubicin 100 mg/m²...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically proven early breast cancer requiring adjuvant chemotherapy (lymph node positive or other features of high risk according to St-Gallen criteria)
- Margins of resection histologically free of invasive carcinoma and ductal carcinoma in situ.
- Radiotherapy performed according to center's policy and always follows completion of adjuvant chemotherapy
- Performance status 0 to 1 on the ECOG scale (Appendix A)
- The determination of ER and PgR is mandatory (immunohistochemical methods required; ER and/or PgR positivity is defined as \> 1% of positive cells). Also determination of Her2neu is mandatory, either by immunohistochemistry or by FISH
- Age \> 18 years and age \<70 years (upper age limit based on the lack of safety data for this population).
- Normal cardiac function (assessment of LVEF by MUGA scan or echocardiography above the lower limit of normal for the institution).
- Adequate organ function (as defined by neutrophils \> 1.5 x109/L, Platelets \> 100 x 109/L, Hemoglobin \> 10 g/dl, total bilirubin \> 1 UNL, ASAT (SGOT) and ALAT (SGPT) \> 1.5 UNL, alkaline phosphatase \> 2.5 UNL, creatinine \> 1.5 mg/dl (150 µmol/L)
- Complete staging work-up within 2 months prior to registration. All patients will have bilateral mammography, chest X-ray (PA and lateral) and/or CT-scan, abdominal ultrasound and/or CT scan, bone scan. In case of positive bone scan suspicious for metastases, bone X-ray (or bone CT-scan on spinal hot spots) is mandatory to rule out the possibility of metastatic disease. Other tests may be performed as clinically indicated.
- Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential. Patients of childbearing potential must implement adequate non-hormonal measures to avoid pregnancy during study treatment (chemotherapy, radiotherapy and endocrine therapy). No pregnant or lactating patients are allowed.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- Exclusion criteria:
- Metastatic disease (M1) or inoperable residual axillary disease
- Prior systemic anticancer therapy for breast cancer (chemotherapy, hormone therapy of immunotherapy)
- Prior radiation therapy for breast cancer.
- Pre-existing motor or sensory neurotoxicity of a severity \> grade 2 by NCI criteria.
- Pregnant or lactating patients
- Other serious illness or medical condition:
- Congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias.
- History of significant neurological or psychiatric disorders that would prohibit the understanding and giving of informed consent.
- Active uncontrolled infection
- Active peptic ulcer, unstable diabetes mellitus.
- Past or current history of other neoplasm except for curatively treated basal cell skin cancer or in situ carcinoma of the cervix.
- Chronic treatment with steroids unless initiated \> 6 months prior to study entry and at low dose (\< 20 mg methylprednisolone or equivalent)
- Concurrent treatment with hormonal replacement therapy: this treatment should be stopped at least 15 days before study entry.
- Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT00256360
Start Date
September 1 2005
End Date
May 1 2006
Last Update
December 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Gasthuisberg Leuven
Leuven, Belgium, B-3000